CMS to Further Review CAS Coverage in January

 

September 28, 2011—The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) of the Centers for Medicare & Medicaid Services (CMS) will convene a meeting on January 25, 2012, for the panel to review available evidence on various clinical strategies for the management of carotid atherosclerosis. Treatments and technologies used in the management of carotid atherosclerosis include medical therapy, carotid endarterectomy, and carotid artery stenting (CAS).

The meeting will focus on the impact on patient health outcomes of these strategies for management of carotid atherosclerosis and prevention of stroke in both symptomatic and asymptomatic patients, as well as evaluate generalizability of the available evidence to patients of differing age, sex, and racial/ethnic backgrounds.

Medicare addresses coverage of CAS in section 20.7 of the national coverage determination (NCD) manual (Pub. 100-03) entitled Percutaneous Transluminal Angioplasty. Sections B2, B3, and B4 of the NCD address coverage of CAS. To access the NCD for percutaneous transluminal angioplasty on the CMS Web site, click here.

MEDCAC meetings are announced in the Federal Register and on the CMS Web site: www.cms.gov. All MEDCAC meeting materials will be available before the meeting on the CMS Medicare Coverage Database Web site.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.